Literature DB >> 20053387

RUNX2 regulates the effects of TNFalpha on proliferation and apoptosis in SaOs-2 cells.

Ghali Olfa1, Chauveau Christophe, Lencel Philippe, Salomez Romain, Hani Khaled, Hardouin Pierre, Broux Odile, Devedjian Jean-Christophe.   

Abstract

The runt-related transcriptional factor RUNX2 is an essential mediator of the osteoblast phenotype and plays a pivotal role in the process of osteoblast differentiation. The involvement of RUNX2 includes the regulation of genes that are important in committing cells to the osteoblast lineage. Increasing evidences are consistent with a requirement of RUNX2 for stringent control of osteoblast proliferation and recent data even suggested that RUNX2 might act as a proapoptotic factor. Among the cytokines described as modulators of osteoblast functions, TNFalpha affects both apoptosis and the differentiation rate from mesenchymal precursor cells of osteoblast. Thus we evaluated on the human osteosarcoma cell line SaOs-2 stably transfected with a RUNX2 dominant negative construct (DeltaRUNX2) the effects of serum and TNFalpha on proliferation and apoptosis. In this study we showed that SaOs-2 clones expressing high levels of DeltaRUNX2 presented a higher proliferation rate than clones transfected with an empty vector. This increase in cell growth was accompanied by a rise in cyclins A1, B1 and E1 expression and a decrease in the cyclin inhibitor p21. Moreover we observed that the expression of the RUNX2 transgene protected the SaOs-2 cells from the antiproliferative and the apoptotic effects induced by TNFalpha. This was accompanied by the inhibition of Bax and activation of Bcl2 expression. Experiments done on SaOs-2 cells transiently transfected with siRNA confirmed that RUNX2 represents a critical link between cell fate, proliferation and growth control. This study also suggested that RUNX2 might control osteoblastic growth depending on the differentiation stage of the cells by regulating expression of elements involved in hormones and cytokines sensitivity. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053387     DOI: 10.1016/j.bone.2009.12.027

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  5 in total

1.  Bone anabolic agents for the treatment of multiple myeloma.

Authors:  Sonia Vallet; Noopur Raje
Journal:  Cancer Microenviron       Date:  2011-12-03

2.  The Role of RUNX2 in Osteosarcoma Oncogenesis.

Authors:  J W Martin; M Zielenska; G S Stein; A J van Wijnen; J A Squire
Journal:  Sarcoma       Date:  2010-12-09

3.  Sodium butyrate has anti-proliferative, pro-differentiating, and immunomodulatory effects in osteosarcoma cells and counteracts the TNFα-induced low-grade inflammation.

Authors:  Silvia Perego; Veronica Sansoni; Giuseppe Banfi; Giovanni Lombardi
Journal:  Int J Immunopathol Pharmacol       Date:  2018 Jan-Dec       Impact factor: 3.219

4.  Loss of Runx2 sensitises osteosarcoma to chemotherapy-induced apoptosis.

Authors:  Alison Roos; Laura Satterfield; Shuying Zhao; Daniel Fuja; Ryan Shuck; M John Hicks; Lawrence A Donehower; Jason T Yustein
Journal:  Br J Cancer       Date:  2015-10-15       Impact factor: 7.640

5.  MicroRNA-150 functions as a tumor suppressor and sensitizes osteosarcoma to doxorubicin-induced apoptosis by targeting RUNX2.

Authors:  Zhonghua Ling; Gentao Fan; Danhua Yao; Jianning Zhao; Yinhua Zhou; Jinzhu Feng; Guangxin Zhou; Yong Chen
Journal:  Exp Ther Med       Date:  2019-11-22       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.